Can I reduce escitalopram (Lexapro) from 20 mg to 15 mg without experiencing discontinuation (withdrawal) symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Reducing Escitalopram from 20 mg to 15 mg: Withdrawal Risk

Yes, you can reduce escitalopram from 20 mg to 15 mg, but withdrawal symptoms are possible and the risk depends on how quickly you taper and your individual sensitivity to discontinuation effects.

Understanding Escitalopram Discontinuation Risk

The FDA label for escitalopram explicitly states that "symptoms associated with discontinuation have been reported" and recommends "a gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" 1. While the label doesn't specify exact tapering schedules, it emphasizes monitoring patients during dose reductions 1.

Escitalopram has a moderate risk profile for discontinuation syndrome:

  • Escitalopram (along with citalopram) carries a relatively lower risk compared to paroxetine, fluvoxamine, and sertraline, which are more commonly associated with severe withdrawal symptoms 2
  • However, discontinuation syndrome still occurs frequently—one study found that 56% (14 of 25 patients) experienced withdrawal symptoms when stopping escitalopram 3
  • Common symptoms include dizziness (44%), muscle tension (44%), chills (44%), confusion or trouble concentrating (40%), amnesia (28%), and crying (28%) 3

Key Factors That Increase Your Risk

Higher doses carry greater risk:

  • Patients taking higher doses of escitalopram had significantly higher rates of discontinuation syndrome compared to those on lower doses 3
  • Since you're at 20 mg (the maximum FDA-approved dose), you're at higher risk than someone on 10 mg 3

The size of your dose reduction matters:

  • A 5 mg reduction (from 20 to 15 mg) represents a 25% decrease, which is relatively modest
  • Research suggests that hyperbolic tapering (reducing the biological effect in equal increments rather than equal dose amounts) minimizes withdrawal symptoms better than linear dose reductions 4

Practical Recommendations

This 5 mg reduction is likely tolerable, but monitor closely:

  • The FDA recommends gradual dose reduction and states that "if intolerable symptoms occur following a decrease in the dose, then resuming the previously prescribed dose may be considered" 1
  • If withdrawal symptoms emerge, you can return to 20 mg and attempt a slower taper 1

Withdrawal symptoms typically appear within 1-3 days of dose reduction 5, so monitor yourself during the first week after the change.

Very slow tapering is recommended for all patients discontinuing escitalopram 3, and this principle applies to dose reductions as well—the slower you go, the lower your risk.

Critical Caveats

  • Traditional guidelines recommending 2-4 week tapers have been shown to provide minimal benefit over abrupt discontinuation and are often not tolerated 4, 6
  • Tapers over months, reaching doses much lower than minimum therapeutic doses, show greater success in reducing withdrawal symptoms 4
  • The 25% reduction you're planning is more aggressive than the hyperbolic tapering approach would suggest, but may still be tolerable given that you're staying within therapeutic range 4

If you develop symptoms like dizziness, sensory disturbances, anxiety, or flu-like symptoms within days of the reduction, these are likely withdrawal effects rather than depression relapse 2, and you should contact your prescriber to discuss either returning to 20 mg or slowing the taper further.

References

Guideline

Citalopram Discontinuation and Sleepwalking

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Managing Fluoxetine Discontinuation Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.